MetaCap

CNS Pharmaceuticals (CNSP) vs Universe Pharmaceuticals (UPC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Universe Pharmaceuticals is the larger company by market cap ($5.4 million vs $5.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CNSP-34.44%UPC-74.91%
+6%-37%-79%
Oct 7, 20261 yearNov 20, 2026
CNSP-33.46%UPC-73.98%
+9%-35%-78%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CNSP versus UPC key metrics
MetricCNSPUPC
Share price$3.56$1.08
Market cap$5.25M$5.43M
1-day change-12.75%-20.59%
YTD return—-71.65%
1-year return—-68.24%
5-year return—-99.99%
EPS (TTM)$-11.80$-1.38
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$17.86B
Revenue growth (YoY)—-22.44%
Net income (latest FY)$-15.85M$-3.67B
Gross margin—35.28%
Operating margin—-16.33%
Net margin—-20.56%
52-week high$10.54$17.96
52-week low$1.90$1.05
Distance from 52-week high-66.22%-93.99%
Analyst consensusnone—
Avg. price target upside+180.90%—
Average volume9.30K176.76K
Shares outstanding1.48M5.01M
Employees8216
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About CNS Pharmaceuticals

CNSP stock →

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

About Universe Pharmaceuticals

UPC stock →

Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications.

Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees

CNSP vs UPC FAQ

Which is bigger, CNS Pharmaceuticals or Universe Pharmaceuticals?

Universe Pharmaceuticals (UPC) is larger, with a market capitalization of $5.43M compared with $5.25M for CNS Pharmaceuticals (CNSP).

Are CNS Pharmaceuticals and Universe Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons